© Fraunhofer SCAI

SYNTHIA: Advancing personalized medicine with synthetic data

The SYNTHIA project applies innovative AI methods to generate synthetic patient data. This approach could help overcome data protection hurdles when sharing medical data, improve predictive models for precision medicine, and even emulate clinical studies. The project is funded by the Innovative Health Initiative (IHI), a partnership for health research and innovation between the EU and Europe’s life science industries.

more info

© Fraunhofer SCAI

© iStock.com/1223190133
Man elegant suit uses futuristic technology. Concept: immersive technology, futuristic medicine, congresses and meetings

The Fraunhofer Center for Digital Diagnostics

Fraunhofer bundles competencies for the targeted development of digital diagnostics solutions. In the Potsdam model region, new solutions and fields of application for digital diagnostics are being researched and developed in order to effectively support patient care and realize value-added potential in the region.

more info

© iStock.com/1223190133

© Ekaterina_1525 - stock.adobe.com / Fraunhofer IZI / Alernon77 - stock.adobe.com / CoreDESIGN - stock.adobe.com / Fraunhofer IZI

Fraunhofer develops automated production technologies for mRNA-based drugs

Coordinated by the Fraunhofer Institute for Cell Therapy and Immunology IZI, seven Fraunhofer institutes are working on the development of automated production technologies for mRNA-based drugs. RNAuto is a Fraunhofer lighthouse project that will receive €8 million in funding from the Fraunhofer-Gesellschaft over the next four years.

more info

© Ekaterina_1525 - stock.adobe.com / Fraunhofer IZI / Alernon77 - stock.adobe.com / CoreDESIGN - stock.adobe.com / Fraunhofer IZI

© links: Fraunhofer IST, Falko Oldenburg | rechts: Fraunhofer IST, Paul Kurze

Plasma treatment during 3D printing improves acceptance of implants

In the High-Performance Center Medical and Pharmaceutical Engineering, researchers at the Fraunhofer Institute for Surface Engineering and Thin Films IST have succeeded in integrating a plasma source into a 3D printer, thereby enabling the surface to be modified. The aim is to treat the scaffolds with plasma during the actual printing process in order to produce the desired properties.

more info

© links: Fraunhofer IST, Falko Oldenburg | rechts: Fraunhofer IST, Paul Kurze

© Fraunhofer IGD

MED²ICIN – Digital patient model as a basis for personalised and cost-optimised treatment

Point-and-click prevention, diagnostics and treatment: That is the vision behind the MED²ICIN lighthouse project. The development of digital models of patients has the potential to revolutionize the healthcare sector. The adoption of innovative digital solutions throughout the treatment process can improve patient care, and also pave the way for treatment that is more targeted, efficacious – and therefore more cost-effective.

more info

© Fraunhofer IGD

Fraunhofer Health

Health research at Fraunhofer addresses the four key areas of medical science — drugs, diagnostics, devices and data, or 4D for short. Many innovations emerge at the interface between medical science, natural science, computer science and engineering. With its emphasis on transdisciplinary research, the Fraunhofer-Gesellschaft offers the perfect environment for close collaboration on health research and the development of cost-intelligent precision medicine for the benefit of patients.

News

 

© vfa

Fraunhofer Gesundheit & vfa

Podcast: Standort auf dem Prüfstand – Wie PROUD Deutschlands Pharmaforschung misst

Wer im internationalen Wettbewerb bestehen will, muss sich messen lassen: die Pharmaforschung steht weltweit im Wettlauf um Talente, Technologien und Investitionen. Aber wie schneidet Deutschland im internationalen Vergleich ab? Wo liegen unsere Stärken – und wo besteht Aufholbedarf?

LinkedIn-Beitrag
 

© vfa

Fraunhofer Gesundheit & vfa

Podcast: Pharmaforschung 2035 – Wie Fraunhofer und vfa Deutschlands Pharmaforschung wieder an die Spitze bringen wollen

Trotz hervorragender Grundlagenforschung liegt Deutschland im internationalen Vergleich bei der Translation in die klinische Entwicklung zurück. Prof. Ulrike Köhl vom Fraunhofer IZI und Dr. Matthias Meergans vom vfa sprechen im Podcast darüber, was sich ändern muss, damit Deutschlands Pharmaforschung wieder an die Spitze gelangt.

LinkedIn-Beitrag
 

© Fraunhofer MEVIS

Fraunhofer Institute for Digital Medicine MEVIS

Using Artificial Intelligence to Detect Changes in Lung Tumors with Greater Speed and Precision

Regular follow-up monitoring is crucial when it comes to treating cancer successfully. In the SPIRABENE project, Fraunhofer Institute for Digital Medicine MEVIS developed a deep learning-based software program which makes it possible to identify disease- and treatment-related changes in tumors in CT images with even greater speed and accuracy, thus improving the chances of recovery and making day-to-day clinical practice easier.

Press Release
 

Fraunhofer Research Institution for Individualized and Cell-Based Medical Engineering IMTE

Opening of an accredited test laboratory for additive manufacturing in medicine at Fraunhofer IMTE

The Fraunhofer Research Institution for Individualized and Cell-based Medical Engineering IMTE today officially opened its new testing laboratory for additive manufacturing in medicine. The official opening was performed by Julia Carstens, State Secretary in the Ministry of Economic Affairs, Transport, Employment, Technology and Tourism of the State of Schleswig-Holstein, and the President of the University of Lübeck, Prof. Dr. Helge Braun.

Press Release
 

Fraunhofer Institute for Biomedical Engineering IBMT

Fraunhofer IBMT part of REACH project consortium on pancreatic ductal adenocarcinoma, one of the most aggressive and lethal forms of cancer

Pancreatic ductal adenocarcinoma (PDAC), while not among the most common cancers, remains one of the deadliest and most treatment-resistant tumors, with a five-year survival rate of just 10 –11%. Despite the introduction of new treatment options, the standard of care has seen little progress over the past three decades, and overall survival still ranges between 6 and 12 months. This poor prognosis is largely due to the tumor’s inherent resistance to chemotherapy and radiotherapy, driven in part by cancer stem cells (CSCs) with unique transcriptional profiles regulated by epigenetic and epitranscriptomic mechanisms. The Fraunhofer Institute for Biomedical Engineering IBMT with its expertise in the development of customized nanoparticles is part of the international consortium.

Press Release
 

© Fraunhofer MEVIS, MRT-Daten mit freundlicher Genehmigung des Universitätsklinikums Erlangen

Fraunhofer Institute for Digital Medicine MEVIS

Innovative Study on Early Detection of Adenomyosis

A research consortium led by University Hospital Erlangen and Charité – Universitätsmedizin Berlin has, for the first time, systematically acquired and analyzed MRI scans of the uterus in both healthy and diseased states as part of the RACOON FADEN project. The image data were evaluated using CuraMate, a modular software platform developed by the Fraunhofer Institute for Digital Medicine MEVIS for the annotation, segmentation, and quantification of medical image features.

Press Release
 

© © Fraunhofer ITEM

Fraunhofer Institute for Toxicology and Experimental Medicine ITEM

Fraunhofer ITEM Researchers Receive Willi Stahlhofen Award for their Publication

A research team from the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM has, for the first time, demonstrated that drug concentrations in the human lung can be measured directly via particles in exhaled breath — a breakthrough with major implications for the targeted development and optimization of inhaled therapies. 

Press Release
 

Fraunhofer-Institut für Translationale Medizin und Pharmakologie ITMP

Klinische Forschung am Fraunhofer ITMP - Für die Gesundheit von morgen

Am Fraunhofer-Institut für Translationale Medizin und Pharmakologie ITMP forschen wir an innovativen Therapien, um Krankheiten besser zu verstehen und zu behandeln. Klinische Studien sind dabei essenziell – sie verbinden Forschung und medizinische Versorgung zum Wohl der Patientinnen und Patienten. Anlässlich des Internationalen Tags der klinischen Forschung am 20 Mai 2025 geben wir in diesem Video Einblicke in unseren Arbeitsalltag – von der Laborarbeit bis zur Betreuung von Patientinnen und Patienten. Dabei zeigen wir, warum klinische Forschung Leben retten kann und wie wir am Fraunhofer ITMP dazu beitragen, die Medizin von morgen zu gestalten.

zur Mediathek
 

© Fraunhofer IMTE

Fraunhofer Research Institution for Individualized and Cell-Based Medical Engineering IMTE

Project TINUSA - Innovative solutions for brain tumor resection

Press Release (German)
 

© Fraunhofer ITEM

Fraunhofer Gesundheit & vfa

Miniature Hearts: Cardiac Organoids With an Immune System

Multicellular human cardiac organoids for drug research. The development of novel therapeutics offer great hope for the fight against widespread diseases such as cancer, but they can impair the cardiovascular system, so development often fails early on. Researchers from the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM and Hannover Medical School have developed a complex cardiac organoid model that can be used to study the potential cardiotoxicity of new medications. Their miniature heart even has an immune system of its own.

Press Release
 

© © Kirstin Linkamp / UKW

Fraunhofer-Institut für Zelltherapie und Immunologie IZI

Mit LION-1 startet erste NCT WERA-Brückenstudie

ROR1-spezifische CAR-T-Zellen gehen erstmals in klinische Prüfung bei Blutkrebs und soliden Tumoren. Die Entwicklung innovativer Immuntherapien ist eines der Ziele des NCT WERA, das seit 2023 Standort des Nationalen Centrums für Tumorerkrankungen NCT ist Hergestellt werden die ROR1-CAR-T-Zellen unter GMP-Bedingungen am Fraunhofer-Institut für Zelltherapie und Immunologie IZI in Leipzig.

zur Meldung (Uniklinikum Würzburg)
 

© Fraunhofer IZFP

Fraunhofer Institute for Biomedical Engineering IBMT

Lösungen für die saarländische Wirtschaft im Bereich komplexer Sensorsysteme: Ministerium für Wirtschaft, Innovation, Digitales und Energie am Fraunhofer ZSI

Press Release (German)

Fraunhofer Institute for Cell Therapy and Immunology IZI

New agent for the treatment of chronic inflammatory bowel diseases

On 1 July, the Fraunhofer Institute for Cell Therapy and Immunology and Otto von Guericke University Magdeburg launched a multi-centre confirmatory preclinical study to evaluate the therapeutic effectiveness of a new agent for the treatment of chronic inflammatory bowel diseases.

 

News

Fraunhofer Institute for Cell Therapy and Immunology IZI

Biomarkers for the successful treatment of tumors in the bone marrow identified

CAR-T cell therapy has been established as an effective treatment for various haematological cancers. However, the treatment does not have the same level of success in all patients. In a current clinical study, researchers from the University of Leipzig Medical Center and the Fraunhofer Institute for Cell Therapy and Immunology IZI have identified various biomarkers which are linked to the response to CAR-T cell therapy in multiple myeloma, a type of bone marrow cancer. The results of their study were published in the renowned journal Nature Cancer.

News

Fraunhofer Match

Do you have a research request?

Fraunhofer Match is the central platform for placing research requests with Fraunhofer.  You tell us about your challenge or project - and Fraunhofer Match will put you in touch with researchers who have the right expertise to help you work out solutions. 

go to Fraunhofer Match-Plattform

Archive

News Archieve

Further notications from our member institutes

Archive